Xenetic Biosciences, Inc. (XBIO) News

Xenetic Biosciences, Inc. (XBIO): $0.68

0.01 (+1.23%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add XBIO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 468

in industry

Filter XBIO News Items

XBIO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest XBIO News From Around the Web

Below are the latest news stories about Xenetic Biosciences Inc that investors may wish to consider to help them evaluate XBIO as an investment opportunity.

JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th

\- Access the event and schedule of presenting companies at virtualinvestorco.com -\- Live video webcast presentations of participating companies followed by interactive Q&A session -PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 /JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2022 Top Picks Conference January 25-27, 2022.

Yahoo | January 12, 2022

Xenetic Biosciences EPS misses by $0.01, beats on revenue

No summary available.

Seeking Alpha | November 12, 2021

Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

* Company advancing XCARTTM pre-clinical development plan toward IND-enabling studies * Strengthened cash position to fund operations through XCART IND filing with recently completed $12.5 million private placement * Continued royalty stream growth through license agreement with PolyXen® platform technologyFRAMINGHAM, MA / ACCESSWIRE / November 12, 2021 / Xenetic Biosciences, Inc.

Yahoo | November 12, 2021

Xenetic Biosciences (NASDAQ:XBIO) Shares Down 2.8%

Xenetic Biosciences Inc (NASDAQ:XBIO)s stock price dropped 2.8% during mid-day trading on Friday . The company traded as low as $1.74 and last traded at $1.76. Approximately 188,287 shares traded hands during mid-day trading, a decline of 94% from the average daily volume of 3,331,003 shares. The stock had previously closed at $1.81. Separately, Zacks []

Dakota Financial News | November 7, 2021

Xenetic Biosciences (NASDAQ:XBIO) Trading Down 2.8%

Xenetic Biosciences Inc (NASDAQ:XBIO)s share price traded down 2.8% during mid-day trading on Friday . The company traded as low as $1.74 and last traded at $1.76. 188,287 shares were traded during trading, a decline of 94% from the average session volume of 3,331,003 shares. The stock had previously closed at $1.81. Separately, Zacks Investment []

Transcript Daily | November 5, 2021

Analysts Estimate Xenetic Biosciences (XBIO) to Report a Decline in Earnings: What to Look Out for

Xenetic Biosciences (XBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | November 4, 2021

Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent - Stocks News Feed

Allowance bolsters intellectual property portfolio for differentiated personalized CAR T platform technology, XCART FRAMINGHAM, MA / ACCESSWIRE / September 9, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (Xenetic or the Company), a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced the United States Read More »Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent

Stocks News Feed | September 9, 2021

Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART Patent

Allowance bolsters intellectual property portfolio for differentiated personalized CAR T platform technology, XCARTFRAMINGHAM, MA / ACCESSWIRE / September 9, 2021 / Xenetic Biosciences, Inc. (NASDA

FinanzNachrichten | September 9, 2021

Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent

Allowance bolsters intellectual property portfolio for differentiated personalized CAR T platform technology, XCARTFRAMINGHAM, MA / ACCESSWIRE / September 9, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced the United States Patent and Trademark Office (USPTO) has issued Xenetic a Notice of Allo

Yahoo | September 9, 2021

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

FRAMINGHAM, MA / ACCESSWIRE / September 8, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced that Jeffrey F.

Yahoo | September 8, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5566 seconds.